
MannKind (MNKD) Stock Forecast & Price Target
MannKind (MNKD) Analyst Ratings
Bulls say
MannKind is expected to see significant revenue growth in the upcoming years, with potential new drug approvals and partnerships presenting major catalysts. Although there are risks associated with commercial execution, clinical trials, and regulations, as well as the potential for a partner to control commercialization of key assets, the company's strong product portfolio and potential for growth make it a compelling investment opportunity. Additionally, upcoming catalysts such as the FUROSCIX ReadyFlow autoinjector PDUFA and TETON-1 study have the potential to significantly increase the company's cash flow and addressable market, making it a high-risk, high-reward investment opportunity.
Bears say
MannKind is facing short-term challenges with lower revenue and earnings reported for 1Q26, but their long-term potential lies in the revenue streams from their partnership with United Therapeutics for Tyvaso DPI, which has yet to be fully appreciated by the market. With multiple upcoming catalysts and a strong balance sheet, there is a favorable risk-reward for MNKD shares despite their challenges in the near-term.
This aggregate rating is based on analysts' research of MannKind and is not a guaranteed prediction by Public.com or investment advice.
MannKind (MNKD) Analyst Forecast & Price Prediction
Start investing in MannKind (MNKD)
Order type
Buy in
Order amount
Est. shares
0 shares